The KLC1 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to eliminate kinesin light chain 1 (KLC1) expression in the HAP1 cell background. This product provides a loss-of-function model for studying the role of KLC1 in intracellular transport, signaling, and neurodegenerative disease mechanisms. The polyclonal nature of the knockout pool ensures representative gene disruption without clonal selection, offering a robust system for functional genomics assays.
HAP1 cells are a near-haploid human cell line derived from KBM-7 chronic myeloid leukemia cells. Their adherent growth and near-haploid karyotype make them an ideal platform for knockout studies, as the single genomic copy simplifies loss-of-function analyses and reduces the influence of allelic variation. This well-characterized model is widely used in genetic screens and targeted gene disruption experiments.
KLC1 encodes a light chain subunit of the kinesin-1 motor complex, which is essential for microtubule-based transport of vesicles, mitochondria, and signaling molecules. The light chain directly interacts with the kinesin heavy chain (KIF5) and links motor activity to specific cargoes via adaptor proteins such as JIP1, JIP3, TRAK1, and HAP1. KLC1-mediated transport is regulated by key kinases including JNK1, GSK3??, and CDK5, and is influenced by amyloid-beta peptide and oxidative stress. Downstream, KLC1 facilitates the movement of mitochondria, APP-containing vesicles, BACE1 vesicles, and autophagosomes. Disruption of KLC1 impairs axonal transport and vesicle trafficking, processes critically involved in neuronal homeostasis and linked to neurodegeneration.
In the HAP1 model, KLC1 knockout enables dissection of kinesin-1-dependent transport pathways with enhanced clarity due to the near-haploid genetic background. This system allows researchers to evaluate the direct effects of KLC1 loss on mitochondrial distribution, cargo trafficking, and signaling dynamics without the compensatory mechanisms present in diploid cells. It is particularly valuable for investigating the molecular pathology of Alzheimer??s disease, hereditary spastic paraplegia, and other conditions where axonal transport failure is a central feature.
Researchers can employ these cells in a variety of assays, including Western blotting and RT-qPCR to confirm gene disruption, immunofluorescence and live-cell vesicle tracking to visualize transport defects, and mitochondrial distribution analysis to assess organelle trafficking. Co-immunoprecipitation can map altered protein interactions, while phospho-JNK analysis provides insights into upstream signaling effects. The model is suitable for drug screening studies aimed at restoring kinesin-dependent transport. For additional product details and technical support, please contact Ascent Research.
